Navigation Links
PAREXEL Enhances Study Start-Up and Recruitment Capabilities With Appointment of Dr. Lars-Olof Eriksson, Formerly With Merck
Date:6/11/2009

t and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC on May 8, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409
    Email: '/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. PAREXEL International to Present at Goldman Sachs Annual Global Healthcare Conference and the Jefferies Annual Healthcare Conference
2. PAREXEL Experts to Address Partnering Best Practices and Innovative Trial Design at Partnerships With CROs Conference
3. PAREXEL Announces Date of Third Quarter Fiscal Year 2009 Earnings Release and Conference Call
4. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
5. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
6. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
7. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
8. PAREXEL Reports Preliminary Second Quarter Results
9. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
10. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
11. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... 2014 A study published in the scientific journal ... Robert Bonin, two researchers at Universit Laval, reveals that ... new method that involves rekindling pain so that it ... novel means to alleviate chronic pain. , The researchers ... Institut universitaire en sant mentale de Qubec (IUSMQ) were ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... , MILFORD, Mass., Sept. 1 ... the Analytical Chemistry Division of the American Chemical Society presented ... Findeis Award for Achievements by a Young Analytical Scientist. Through ... Engen has pioneered the combined use of hydrogen-deuterium ...
... SAN ANTONIO, Sept. 1 Mission Pharmacal ... a one-of-a-kind formulation that provides fast, effective relief from the ... Esrubar, L.P., and formerly distributed by Beta Dermaceuticals, Inc. ... Mission Pharmacal,s strategy to accelerate growth by continuing to expand ...
... , PLANO, Texas, Sept. 1 American Institute for ... metro-Dallas area, is using Artefill to help patients fight wrinkles for ... only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines ... Raphael and Dr. Scott Harris have been using to treat patients ...
... , , SCHAUMBURG, Ill., Sept. 1 ... Veterinary Medical Association (AVMA) reveal an economic mixed bag when it ... , The survey results appear in the Journal ... 2009, article entitled, "Employment, starting salaries, and educational indebtedness of year-2009 ...
... , SAN DIEGO, Sept. 1 Volcano Corporation (Nasdaq: ... products for the diagnosis and treatment of coronary and peripheral artery disease, ... Healthcare Conference 2009 on Wednesday, September 9. , , ... a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). , , ...
... , , , ... showed that in patients treated with LIVALO (pitavastatin), high-density ... patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results ... have comparable efficacy to atorvastatin and simvastatin, as measured ...
Cached Medicine News:Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 2Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 3Health News:Mission Pharmacal Acquires Dr. Smith's Diaper Ointment 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 3Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 2Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 3Health News:Volcano Corporation Presentation at Weisel Conference to be Webcast 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 3Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 4Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 5
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CHAPEL HILL, N.C. , June 11 ... groups is a critical part of educating patients and ... consumers as they seek out information on new therapies, ... deep-dive interviews with selected participants, Best Practices, LLC conducted ...
... HILL, N.C. , June 11 The bio-pharma mega-mergers that ... Merck + Schering-Plough - are now in the critical post-integration period and ... their integration plans. , , ... It is too early for final verdicts, but clearly one M&A issue ...
Cached Medicine Technology:Collaborating with Patient Advocacy Groups to Educate Physicians, Patients and Thought Leaders 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: